Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504781 | 0.90 | HRH3 (0.41) | CHRNA7KCNH2OPRK1OPRM1ROCK2 | |
| SCHEMBL4519262 | 0.90 | OPRK1 (0.33) | KCNH2OPRK1OPRM1ROCK2ROCK1 | |
| SCHEMBL4508291 | 0.89 | KCNH2 (0.37) | CHRNB2CHRNA7CHRNA4KCNH2OPRK1 | |
| SCHEMBL4518555 | 0.87 | OPRM1 (0.40) | KCNH2OPRK1OPRM1ROCK2ROCK1 | |
| SCHEMBL4511833 | 0.87 | OPRM1 (0.38) | KCNH2OPRK1OPRM1ROCK2ROCK1 | |
| SCHEMBL4521267 | 0.82 | ROCK2 (0.37) | CHRNB2CHRNA7CHRNA4KCNH2OPRK1 | |
| SCHEMBL4508407 | 0.80 | HRH3 (0.39) | CHRNA7KCNH2OPRK1OPRM1OPRD1 | |
| SCHEMBL4515040 | 0.80 | CYP2D6 (0.34) | KCNH2OPRK1OPRM1 | |
| SCHEMBL4508235 | 0.79 | KCNH2 (0.36) | KCNH2OPRK1OPRM1 | |
| SCHEMBL4518047 | 0.79 | CLK4 (0.37) | KCNH2OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | claimed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CHRNB2 116/4885CHRNA7 78/4885CHRNA4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.